🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Midcap stock falls 3% after shares worth ₹ 1,815 Cr exchanged hands 

Published 19-06-2024, 11:57 am
Midcap stock falls 3% after shares worth ₹ 1,815 Cr exchanged hands

On Wednesday, the share price of a generic injectable-focused pharmaceutical company moved down by 3.6 percent on BSE to Rs. 1,771.05, after nearly 1.02 crore equity share, equivalent to a 6.2 percent stake, worth Rs. 1,815 crore exchanged hands on June 19th via a block deal.

With a market capitalisation of Rs. 29,760.75 crore, at 10:36 a.m., the shares of Gland Pharma (NS:GLAD) Limited were trading in the red at Rs. 1,801.95, down by 2 percent, compared to its previous closing price of Rs. 1,838.5.

Is Gland Pharma a buy or sell? Click here to get an InvestingPro subscription for a special discount of 74% at an unbelievable price of only Rs 182 per month

The above link works best from a laptop/desktop and not apps.

A few sources stated that the Shanghai-based Fosun Pharmaceutical Group, a company’s promoter, was most likely the seller of Gland Pharma since it was planning to cut off a 5 percent stake in the business through a block deal, pricing the sale at $172 million.

According to the report, the seller is a subsidiary of Shanghai Fosun Pharma (Group) Co., and the floor price was fixed at Rs. 1,750 apiece, representing a nearly 5 percent discount to Gland Pharma’s closing price on Tuesday, with a 90-day lock-in period on the additional sale of shares.

In order to strengthen its balance sheet, Fosun Pharma was reportedly seeking to sell its stake in the business over the next few months, unless buyout companies step in with an offer.

Fosun Pharma, the listed subsidiary of Chinese billionaire and investor Guo Guangchang’s Fosun International, owns 57.86 percent of Gland Pharma.

For around $1.1 billion, Fosun Pharma acquired a 74 percent stake in Gland Pharma in 2017 from a consortium that included KKR & Co. Three years later, in 2020, the company went public in Mumbai.

Through the IPO, Gland Pharma raised Rs. 6,499 crore, out of which, Rs. 1,944 crore was raised from 70 anchor investors. The stock was listed at a 14 percent premium, and the issue price was Rs. 1,500.

In terms of financials, the company’s revenue from operations grew by nearly 95.8 percent YoY from Rs. 785 crore in Q4 FY22-23 to Rs. 1,537.45 crore in Q4 FY23-24, accompanied by a rise in the after-tax profit of 144.5 percent YoY, from Rs. 78.7 crore to Rs. 192.42 crore, during the same period.

The stock has delivered positive returns of nearly 76 percent in the last one year, but has given 5.5 percent of negative returns year-to-date.

Established in 1978, Gland Pharma Limited is one of the largest and fastest-growing injectable-focused companies and operates primarily under a business-to-business (B2B) model with a track record in the development, manufacturing, and marketing of sterile injectables.

The company has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Introducing InvestingPro

Through InvestingPro, you can beat the markets with premium insights:

  • Find Undervalued/Overvalued Stocks: Reveal the unbiased Fair Value of any stock based on 1,200+ premium metrics, covering 180,000+ companies worldwide.
  • Instant Financial Bottom Line: Make fully-informed investing decisions with ProTips, bite-size insights that flag risks and rewards on any stock.
  • Discover Overlooked Stocks With Pre-Built Screeners: Find the ideal value stocks to match your investing style, all based on 100% trusted data.
  • Get AI-Enhanced Stock Picks: Receive regularly updated ProPicks for any investing strategy, each with a proven track record to beat the S&P 500
  • Boost Your Picks with Data: Instantly see a company's long-term sustainability and Financial Health to know if it's truly a solid investment.
  • Always Pick the Winner: Make instant Peer Comparisons based on over a dozen valuation benchmarks to ensure you always select a top dog.
  • Get Ideas From Top-Performing Portfolios: See the investments of any firm, fund or private investor with over $100 million in holding assets to discover new ideas.

Now, coming to the great news! For the benefit of our users, we have reduced the prices on all of our Pro and Pro+ plans by almost 74% for a limited period.

Click here to get an InvestingPro subscription for a special discount of 74% at an unbelievable price of only Rs 182 per month

The above link works best from a laptop/desktop and not apps.

Written by Shivani Singh


The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Midcap stock falls 3% after shares worth ₹ 1,815 Cr exchanged hands appeared first on Trade Brains.

Read More

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.